Please login to the form below

Not currently logged in
Email:
Password:

Cosentyx

This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

The risk of flare was reduced by 72% for patients on Cosentyx for two years compared with patients on placebo. ... Safety in this paediatric population was consistent with the known safety profile of Cosentyx for the treatment of adult and paediatric

Latest news

More from news
Approximately 32 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Maker Projects

    Our clients include: The NHS NWEH Cancer Research Cosentyx / Novartis Brilinta / AstraZeneca Port of Call We have branches in Manchester and London - to find out more: www.makerprojects.co.

  • 90TEN nominated for five Communiqué Awards

    Year. 90TEN’s work with Novartis on the global launch of Cosentyx is nominated for Excellence in Media Relations.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...